Evaluation of the Effect of Ixekizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients With Moderate-to-Severe Plaque Psoriasis
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 18 Aug 2017
At a glance
- Drugs Caffeine (Primary) ; Dextromethorphan (Primary) ; Ixekizumab (Primary) ; Midazolam (Primary) ; Omeprazole (Primary) ; Vitamin K (Primary) ; Warfarin (Primary)
- Indications Plaque psoriasis
- Focus Pharmacokinetics
- Sponsors Eli Lilly
- 04 Aug 2017 Status changed from recruiting to active, no longer recruiting.
- 23 Dec 2016 Status changed from not yet recruiting to recruiting.
- 19 Dec 2016 New trial record